Takeda announced positive Phase 3 head-to-head data for its investigational drug zasocitinib, showing superior efficacy against deucravacitinib in treating plaque psoriasis. This strong clinical data, particularly the higher rates of complete skin clearance, positions zasocitinib favorably for regulatory approval and market penetration, potentially impacting the competitive landscape for psoriasis treatments.
Takeda has released compelling Phase 3 head-to-head data for zasocitinib, demonstrating its statistical superiority over Bristol Myers Squibb's deucravacitinib in treating plaque psoriasis. This is a significant development as zasocitinib achieved substantially higher rates of complete skin clearance (PASI 100) and PASI 90 as early as week 8 and maintained durable results. This positive data, especially given zasocitinib is currently under FDA and EMA review, significantly strengthens Takeda's position in the competitive psoriasis market. For traders, this presents a short-term opportunity for Takeda (TAK) due to increased confidence in its pipeline and a potential long-term threat to Bristol Myers Squibb (BMY) as deucravacitinib faces a more potent competitor, potentially impacting its market share and revenue projections in the psoriasis segment.